BCL2 and B-cell chronic lymphocytic leukemia: Moreover, novel targeted drugs for CLL, including Bruton’s tyrosine kinase inhibitors (BTKi; ibrutinib and acalabrutinib), BCL2 inhibitors (venetoclax), and phosphatidylinositol 3-kinase inhibitors (PI3Ki; idelalisib and duvelisib), have improved the prognosis of CLL patients in developed countries significantly in the last 10 years (7).